Revised earnings per share (EPS) for Tempest Therapeutics is reported as -$2.07, surpassing expectations by $0.58.

Revised earnings per share (EPS) for Tempest Therapeutics is reported as -$2.07, surpassing expectations by $0.58.

Tempest Therapeutics Reports Q2 2025 Financial Results

Tempest Therapeutics, a biotechnology company focused on the development of novel treatments, has released its financial report for the second quarter of 2025. The report shows a net loss of $7.9 million, with GAAP EPS of -$2.07, beating estimates by $0.58.

The company ended the quarter with $14.3 million in cash and cash equivalents, a decrease of $26.2 million from the $30.3 million it had at the end of 2024. This decrease is primarily due to cash used in operating activities.

The report indicates that research and development expenses declined to $3.9 million from $5.8 million year-over-year, while general and administrative expenses rose slightly to $4.1 million, mainly because of one-time employee separation costs.

However, Tempest Therapeutics managed to raise $4.1 million net from a registered direct offering and $2.8 million from an at-the-market program in June 2025, which helped offset some of the cash burn.

Key Financial Details

• Net loss: $7.9 million
• GAAP EPS: -$2.07 (beat by $0.58)
• Cash and cash equivalents: $14.3 million (down from $30.3 million in Dec 2024)
• R&D expenses: $3.9 million (down from $5.8 million in Q2 2024)
• General & administrative expenses: $4.1 million (up from $3.7 million)
• Capital inflow: $4.1 million net proceeds from June registered direct offering + $2.8 million net from at-the-market offering

The decline in cash is mainly due to cash used in operations; however, the capital raised via offerings partly offset the cash burn. There is no specific separate line item disclosed for capital expenditures, indicating minimal or no significant investment spending beyond operating cash outflows.

Unfortunately, the financial report does not provide information about Tempest Therapeutics' revenue for Q2 or any significant financing during the quarter.

Tempest Therapeutics' stock is traded on NASDAQ under the ticker symbol TPST.

In summary, Tempest’s Q2 2025 financials reflect ongoing investment in R&D with reduced expenses, a manageable net loss improving year-over-year, substantial cash burn, and strategic capital raises to sustain operations.

Investing in Tempest Therapeutics' stock might be of interest to those involved in business, given the company's financial results for Q2 2025. The biotech firm reported a decline in cash due to operating activities, but raised capital through offerings to offset some of the cash burn. Despite a manageable net loss and reduced R&D expenses, the company did not disclose any significant financing during the quarter or its revenue for Q2.

Read also: